Objective: To compare the complications among preterm infants treated with two different natural surfactants.
Methods: In a randomized clinical trial, 150 preterm infants with Respiratory distress syndrome (RDS) treated with exogenous surfactant, were enrolled in the study. Group A consisted of 79 neonates that received poractant (curosurf). Seventy one newborn infants in group B were treated with beractant (Survanta).
Results: The mean gestational age for group A and B were 29.40+/-2.90 wk and 29.50+/-2.73 wk (P=0.82), respectively. The demographic and clinical variables were similar in both groups. The mean duration of intubation (as a primary outcome) was significantly shorter in infants treated with poractant (3.13+/-1.80 vs 4.06+/-2.7 days p=0.05). The mean duration of need for oxygen and hospitalization of patients in group A and B were 17.73+/-22.25 vs 19.14+/-17.85 days (p=0.67) and 24.89+/-26.41 vs 29.14+/-23.54 days (p= 0.32), respectively. There was no significant difference between groups with respect to mortality and morbidity, including pulmonary hemorrhage, intraventricular hemorrhage (IVH), patent ductus arteriosus, sepsis, and bronchopulmonary dysplasia (secondary outcome).
Conclusions: In this study, infants who received poractant had shorter duration of intubation than infants treated with beractant, without any difference in the duration of oxygen therapy or hospitalization. There was no significant superiority of poractant over beractant.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12098-010-0097-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Introduction Respiratory distress syndrome (RDS) is a leading cause of morbidity and mortality among preterm infants, necessitating effective treatment strategies. This study compared the efficacy of Beractant (SURVANTA®) to Poractant alfa (CUROSURF®) in treating RDS in preterm infants admitted to Tawam Hospital in the UAE. Methodology This retrospective study included preterm infants from 23+0 to 36+6 weeks of gestation with a diagnosis of RDS and treatment by Beractant or Poractant alfa within 48 hours of life between January 2020 and March 2023.
View Article and Find Full Text PDFComparative biophysical study of clinical surfactants using constrained drop surfactometry.
Am J Physiol Lung Cell Mol Physiol
October 2024
Department of Mechanical Engineering, University of Hawaii at Manoa, Honolulu, Hawaii, United States.
Surfactant replacement therapy is crucial in managing neonatal respiratory distress syndrome (RDS). Currently licensed clinical surfactants in the United States and Europe, including Survanta, Infasurf, Curosurf, and Alveofact, are all derived from bovine or porcine sources. We conducted a comprehensive examination of the biophysical properties of these four clinical surfactant preparations under physiologically relevant conditions, using constrained drop surfactometry (CDS).
View Article and Find Full Text PDFComparison of efficacy between beractant and poractant alfa in respiratory distress syndrome among preterm infants (28-33 weeks gestational age) using the less invasive surfactant administration (LISA) technique: A randomized controlled trial.
J Perinatol
April 2024
Department of Pharmacology, Institute of Post Graduate Medical Education & Research and SSKM Hospital, 244, A J C Bose Road, Kolkata, PIN-700020, India.
Article Synopsis
- Exogenous surfactant therapy is crucial for treating respiratory distress syndrome (RDS) in preterm infants, and the study focuses on the effectiveness of less invasive surfactant administration (LISA) using two types: beractant and poractant alfa.
- In a randomized controlled trial, 120 preterm infants (28-33 weeks) with RDS were treated with either beractant (100 mg/kg) or poractant-alfa (200 mg/kg), with intubation needs within 72 hours as the primary outcome.
- Results showed both treatments required intubation in 3.3% of cases, with no significant differences in effectiveness, but beractant was more cost-effective than poractant
Gastric Aspirate Phosphatidylcholine Species in Preterm Neonates Receiving Aerosolized Surfactant.
J Pediatr
December 2023
Department of Pathology, Lipidomics Core Facility, Wayne State University School of Medicine, Detroit, MI.
Objective: To characterize phosphatidylcholine (PC) molecular species in serial gastric aspirates as biomarkers for lung maturity, delivery of aerosolized surfactant (AS), and need for intubation.
Methods: In a phase II clinical trial of aerosolized surfactant in preterm neonates with respiratory distress syndrome receiving noninvasive ventilation, infants received a maximum of 2 doses of nebulized beractant. Gastric aspirates were collected before and after each dose and were analyzed for PCs using liquid chromatography mass spectrometry.
Comparison of Beractant Administration by Thin Catheter vs Intubation-Surfactant-Extubation (INSURE) in Preterm Infants Less than 34 Weeks Gestational Age with Respiratory Distress Syndrome - A Single Centre Experience.
J Neonatal Perinatal Med
July 2023
Department of Neonatology, Lokmanya Tilak Municipal Medical College and General Hospital, Sion, Mumbai.
Background: Poractant administration with thin catheter is gradually gaining popularity compared to the INSURE technique. However, there is little evidence to use thin catheters for administration of beractant. With this background, we compared the effect of beractant administration with INSURE vs thin catheter in preterm infants less than 34 weeks with RDS on death/chronic lung disease (CLD).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!